1. Home
  2. AEAQ vs ALEC Comparison

AEAQ vs ALEC Comparison

Compare AEAQ & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEAQ

Activate Energy Acquisition Corp. Class A Ordinary Share

N/A

Current Price

$9.91

Market Cap

309.7M

Sector

N/A

ML Signal

N/A

Logo Alector Inc.

ALEC

Alector Inc.

HOLD

Current Price

$2.42

Market Cap

262.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEAQ
ALEC
Founded
2025
2013
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.7M
262.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
AEAQ
ALEC
Price
$9.91
$2.42
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.83
AVG Volume (30 Days)
154.7K
697.9K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$21,045,000.00
Revenue This Year
N/A
$18.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.87
$0.88
52 Week High
$9.96
$3.40

Technical Indicators

Market Signals
Indicator
AEAQ
ALEC
Relative Strength Index (RSI) 51.16 59.26
Support Level $9.87 $1.89
Resistance Level $9.95 $2.55
Average True Range (ATR) 0.03 0.19
MACD 0.00 0.03
Stochastic Oscillator 44.44 70.07

Price Performance

Historical Comparison
AEAQ
ALEC

About AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share

Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About ALEC Alector Inc.

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Share on Social Networks: